Pascal and Francis Bibliographic Databases

Help

Search results

Your search

kw.\*:("Elvitégravir")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 60

  • Page / 3
Export

Selection :

  • and

Pharmacokinetics of Once-Daily Boosted Elvitegravir When Administered in Combination With Acid-Reducing AgentsRAMANATHAN, Srinivasan; MATHIAS, Anita; XUELIAN WEI et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 64, Num 1, pp 45-50, issn 1525-4135, 6 p.Article

Pharmacokinetics and Bioavailability of an Integrase and Novel Pharmacoenhancer-Containing Single-Tablet Fixed-Dose Combination Regimen for the Treatment of H IVGERMAN, Polina; WARREN, David; WEST, Steve et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 55, Num 3, pp 323-329, issn 1525-4135, 7 p.Article

Pharmacokinetic Interaction of Ritonavir-Boosted Elvitegravir and MaravirocRAMANATHAN, Srinivasan; ABEL, Samantha; TWEEDY, Sarah et al.Journal of acquired immune deficiency syndromes (1999). 2010, Vol 53, Num 2, pp 209-214, issn 1525-4135, 6 p.Article

Effect of Ritonavir-Boosted Tipranavir or Darunavir on the Steady-State Pharmacokinetics of ElvitegravirMATHIAS, Anita A; HINKLE, John; GONG SHEN et al.Journal of acquired immune deficiency syndromes (1999). 2008, Vol 49, Num 2, pp 156-162, issn 1525-4135, 7 p.Article

Pharmacologie des inhibiteurs de l'intégrase du VIH = Clinical pharmacology of HIV integrase inhibitorsSOLAS-CHESNEAU, C; QUARANTA, S; LACARELLE, B et al.Virologie (Montrouge). 2009, Vol 13, Num MAI, issn 1267-8694, S25-S34, NSArticle

The Pharmacokinetic and Pharmacodynamic Interactions Between Buprenorphine/Naloxone and Elvitegravir/ Cobicistat in Subjects Receiving Chronic Buprenorphine/ Naloxone TreatmentBRUCE, Robert Douglas; WINKLE, Peter; CUSTODIO, Joseph M et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 63, Num 4, pp 480-484, issn 1525-4135, 5 p.Article

Clinical Pharmacokinetic and Pharmacodynamic Profile of the HIV Integrase Inhibitor ElvitegravirRAMANATHAN, Srinivasan; MATHIAS, Anita A; GERMAN, Polina et al.Clinical pharmacokinetics. 2011, Vol 50, Num 4, pp 229-244, issn 0312-5963, 16 p.Article

Integrase Inhibitors : A New Treatment Option for Patients with Human Immunodeficiency Virus InfectionCORRELL, Todd; KLIBANOV, Olga M.Pharmacotherapy. 2008, Vol 28, Num 1, pp 90-101, issn 0277-0008, 12 p.Article

Next-Generation Integrase Inhibitors: Where to After Raltegravir?KARMON, Sharon L.Drugs (Basel). 2013, Vol 73, Num 3, pp 213-228, issn 0012-6667, 16 p.Article

Broad Antiretroviral Activity and Resistance Profile of the Novel Human Immunodeficiency Virus Integrase Inhibitor Elvitegravir (JTK-303/GS-9137)SHIMURA, Kazuya; KODAMA, Eiichi; KANO, Mitsuki et al.Journal of virology. 2008, Vol 82, Num 2, pp 764-774, issn 0022-538X, 11 p.Article

A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infection: 96-Week ResultsELION, Richard; MOLINA, Jean-Michel; CHUCK, Steven L et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 63, Num 4, pp 494-497, issn 1525-4135, 4 p.Article

HIV-2 Antiviral Potency and Selection of Drug Resistance Mutations by the Integrase Strand Transfer Inhibitor Elvitegravir and NRTIs Emtricitabine and Tenofovir In VitroANDREATTA, Kristen; MILLER, Michael D; WHITE, Kirsten L et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 62, Num 4, pp 367-374, issn 1525-4135, 8 p.Article

Potential of novel antiretrovirals to modulate expression and function of drug transporters in vitroZEMBRUSKI, Nadine Cécile Luise; BÜCHEL, Gabriele; JÖDICKE, Lisa et al.Journal of antimicrobial chemotherapy (Print). 2011, Vol 66, Num 4, pp 802-812, issn 0305-7453, 11 p.Article

Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infectionGARRIDO, Carolina; GERETTI, Anna Maria; ZAHONERO, Natalia et al.Journal of antimicrobial chemotherapy (Print). 2010, Vol 65, Num 2, pp 320-326, issn 0305-7453, 7 p.Article

Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 StudyCASTAGNA, Antonella; MAGGIOLO, Franco; DOROANA, Manuela et al.The Journal of infectious diseases. 2014, Vol 210, Num 3, pp 354-362, issn 0022-1899, 9 p.Article

Dolutegravir: A New Integrase Strand Transfer Inhibitor for the Treatment of HIVSHAH, Bhavik M; SCHAFER, Jason J; DESIMONE, Joseph A et al.Pharmacotherapy. 2014, Vol 34, Num 5, pp 506-520, issn 0277-0008, 15 p.Article

A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection: Analysis of Week 96 ResultsROCKSTROH, Jürgen K; DEJESUS, Edwin; FORDYCE, Marshall W et al.Journal of acquired immune deficiency syndromes (1999). 2013, Vol 62, Num 5, pp 483-486, issn 1525-4135, 4 p.Article

Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143METIFIOT, Mathieu; VANDEGRAAFF, Nick; MADDALI, Kasthuraiah et al.AIDS (London). 2011, Vol 25, Num 9, pp 1175-1178, issn 0269-9370, 4 p.Article

Integrase Inhibitors: A Novel Class of Antiretroviral AgentsSCHAFER, Jason J; SQUIRES, Kathleen E.The Annals of pharmacotherapy. 2010, Vol 44, Num 1, pp 145-156, issn 1060-0280, 12 p.Article

Activity of Elvitegravir, a Once-Daily Integrase Inhibitor, against Resistant HIV Type 1: Results of a Phase 2, Randomized, Controlled, Dose-Ranging Clinical TrialZOLOPA, Andrew R; BERGER, Daniel S; LAMPIRIS, Harry et al.The Journal of infectious diseases. 2010, Vol 201, Num 6, pp 814-822, issn 0022-1899, 9 p.Article

Pharmacokinetics and Safety of Boosted Elvitegravir in Subjects with Hepatic ImpairmentCUSTODIO, Joseph M; RHEE, Martin; GONG SHEN et al.Antimicrobial agents and chemotherapy. 2014, Vol 58, Num 5, pp 2564-2569, issn 0066-4804, 6 p.Article

Investigation of the Interactions between Methadone and Elvitegravir-Cobicistat in Subjects Receiving Chronic Methadone MaintenanceBRUCE, R. Douglas; WINKLE, P; CUSTODIO, J. M et al.Antimicrobial agents and chemotherapy. 2013, Vol 57, Num 12, pp 6154-6157, issn 0066-4804, 4 p.Article

Broad Phenotypic Cross-Resistance to Elvitegravir in HIV-Infected Patients Failing on Raltegravir-Containing RegimensGARRIDO, Carolina; VILLACIAN, Jorge; ZAHONERO, Natalia et al.Antimicrobial agents and chemotherapy. 2012, Vol 56, Num 6, pp 2873-2878, issn 0066-4804, 6 p.Article

Dose-Response of Ritonavir on Hepatic CYP3A Activity and Elvitegravir Oral ExposureMATHIAS, A. A; WEST, S; HUI, J et al.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 1, pp 64-70, issn 0009-9236, 7 p.Article

Pharmacokinetics of elvitegravir and etravirine following coadministration of ritonavir-boosted elvitegravir and etravirineRAMANATHAN, Srinivasan; KAKUDA, Thomas N; MACK, Rebecca et al.Antiviral therapy (London). 2008, Vol 13, Num 8, pp 1011-1017, issn 1359-6535, 7 p.Article

  • Page / 3